Corbus reports CRB-701 42.9% cORR in 2L OPSCC at 3.6 mg/kg; registrational study planned summer 2026

Corbus Pharmaceuticals Holdings, Inc.

cORR 42.9% (9/21) in 2L OPSCC at 3.6 mg/kg; median DOR 6.3 mo, PFS 5.6 mo.
cORR 34.4% (11/32) in 2L cervical cancer at 3.6 mg/kg; 2 complete responses, DOR 8.0 mo.
Safety: treatment discontinuations 2.8%; no Grade 5 events; ocular AEs manageable.
FDA alignment on registrational trials: TEMPO-1 (OPSCC, n=250) to start summer 2026.
85.4% of OPSCC patients HPV+; 8 of 9 responders in OPSCC were HPV+.

item 7.01 item 8.01 item 9.01

Featured in Daily 8-K Digest

Selected #10 for 2026-05-26. Read digest

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-238059
form_type: 8-K
ticker: CRBP
cik: 0001595097
company_name: Corbus Pharmaceuticals Holdings, Inc.
filed_at: 2026-05-26T12:56:06+00:00
discovered_at: 2026-05-26T13:00:00.421774+00:00
generated_at: 2026-05-26T13:00:18.417122+00:00
sec_items: ["7.01", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-238059
json_url: https://secwatch.observer/filing/0001193125-26-238059.json
markdown_url: https://secwatch.observer/filing/0001193125-26-238059.md
text_url: https://secwatch.observer/filing/0001193125-26-238059.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1595097/000119312526238059/0001193125-26-238059-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1595097/000119312526238059/crbp-20260526.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-238059

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.